Q-omics provides the consensus-scored C1orf87 profile across patient tissues and cancer cell-line models. C1orf87 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, C1orf87 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, C1orf87 RNA expression shows 8,530 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, KICH, and KIRP as cancer lineages where C1orf87 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf87 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf87 survival associations across molecular data types. C1orf87 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf87 RNA expression–survival associations across cancer types. High C1orf87 expression shows unfavorable associations in LGG, KIRC, OV and DLBC, but favorable associations in ACC and LIHC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for C1orf87 RNA expression.
This table summarizes C1orf87 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C1orf87. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf87 shows lower tumor expression in KICH, LUAD, KIRC, LUSC, KIRP and THCA. The KICH box plot shows higher C1orf87 RNA expression in normal versus tumor tissue (log2 FC = −0.345, t-test p < 0.001).
This table shows molecular features associated with C1orf87 in patient tissues and cancer cell lines. In patient samples, C1orf87 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf87 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
